Indications for use of Afobazol are:

It is used in adults with anxiety conditions: generalized anxiety disorders, neurasthenia, adaptation disorders, in patients with various somatic diseases (bronchial asthma, irritable bowel syndrome, systemic lupus erythematosus, ischemic heart disease, hypertension, arrhythmias), dermatological, oncological and other diseases. In the treatment of sleep disorders associated with anxiety, neurocirculatory dystonia, premenstrual syndrome, alcohol withdrawal syndrome, to alleviate the withdrawal syndrome when smoking cessation.

  PHARMACHOLOGIC EFFECT

Afobazole is a selective non-benzodiazepine anxiolytic. By acting on sigma-1 receptors in the nerve cells of the brain, Afobazol stabilizes GABA / benzodiazepine receptors and restores their sensitivity to endogenous mediators of inhibition. It also increases the bioenergetic potential of nerve cells and protects them from damage (has a neuroprotective effect). The action of the drug is realized mainly in the form of a combination of anxiolytic (anti-anxiety) and mild stimulating (activating) effects. Afobazol reduces or eliminates feelings of anxiety (concern, bad feelings, apprehension, irritability), tension (fearfulness, tearfulness, anxiety, inability to relax, insomnia, fear), somatic manifestations of anxiety (muscle, sensory, cardiovascular, respiratory, gastrointestinal intestinal symptoms), autonomic disorders (dry mouth, sweating, dizziness), cognitive disorders (difficulty concentrating, impaired memory). The use of the drug is especially indicated in persons with predominantly asthenic personality traits in the form of anxious suspiciousness, uncertainty, increased vulnerability and emotional lability, a tendency to emotional-stressful reactions. The effect of the drug develops on the 5-7th day of treatment. The maximum effect is achieved by the end of 4 weeks of treatment and remains after the end of treatment for an average of 1-2 weeks. Afobazole does not cause muscle weakness, drowsiness and does not have a negative effect on concentration and memory. When using it, drug dependence is not formed and the withdrawal syndrome does not develop. After oral administration, it is well and quickly absorbed from the gastrointestinal tract. The maximum concentration of the drug in plasma is 0.130 + 0.073 μg / ml; the time to reach the maximum concentration is 0.85 + 0.13 hours. Metabolism: Afobazole undergoes the "first pass effect" through the liver, the main directions of metabolism are hydroxylation at the aromatic ring of the benzimidazole cycle and oxidation at the morpholine fragment. Afobazole is intensively distributed over well-vascularized organs, it is characterized by rapid transfer from the central pool (blood plasma) to the peripheral (highly vascularized organs and tissues). The half-life of Afobazol when taken orally is 0.82 + 0.54 hours. The short half-life is due to the intensive biotransformation of the drug and the rapid distribution from blood plasma to organs and tissues. The drug is excreted mainly in the form of metabolites and partially unchanged in the urine and feces.